Sellas Life Sciences Group Inc

SLS.US
Healthcare · Biotechnology
10.09
-0.75 (-6.88%)
USD · NASDAQ

Company Information

Company Name
Sellas Life Sciences Group Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US81642T2096
CIK: 0001390478
CUSIP: 74978T109
Currency: USD
Full Time Employees: 13
Phone: 646 200 5278
Fiscal Year End: December
IPO Date: Dec 29, 2017
Description:

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Address:

7 Times Square, New York, NY, United States, 10036

People

Directors & Officers

Name Title Year Born
Dr. Angelos M. Stergiou M.D., ScD h.c. Founder, President, CEO & Director 1976
Mr. John Thomas Burns CPA Senior VP & CFO 1985
Dr. Dragan Cicic M.D., MBA Senior VP & Chief Development Officer 1963
Ms. Stacy E. Yeung VP, General Counsel & Corporate Secretary NA
Mr. Andrew Elnatan Senior VP of Regulatory Affairs, CMC & Quality NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Nov 19, 2025 Katherine Bach Kalin N/A Purchase 63.40K $1.59 $100.81K
Jun 12, 2025 Nostrand Robert L Van N/A Purchase 10.00K $1.48 $14.80K
May 30, 2025 Jane Wasman N/A Purchase 20.00K $1.69 $33.80K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 12.20M Mar 31, 2026 6.20% $0.00 61.76%
Vanguard Group Inc 8.47M Dec 31, 2025 4.31% $0.00 23.79%
State Street Corp 8.40M Mar 31, 2026 4.27% $0.00 283.72%
Vanguard Capital Management, LLC 7.53M Mar 31, 2026 3.83% $0.00 0.00%
Geode Capital Management, LLC 3.91M Mar 31, 2026 1.99% $0.00 27.14%
Marshall Wace Asset Management Ltd 2.04M Mar 31, 2026 1.04% $0.01 51.95%
JONES FINANCIAL COMPANIES LLLP 1.68M Mar 31, 2026 0.85% $0.00 290.24%
Vanguard Portfolio Management, LLC 1.46M Mar 31, 2026 0.74% $0.00 0.00%
Morgan Stanley - Brokerage Accounts 1.34M Mar 31, 2026 0.68% $0.00 49.99%
Northern Trust Corp 1.28M Mar 31, 2026 0.65% $0.00 37.09%
Dagco Inc 1.23M Jun 30, 2026 0.63% $3.36 19.80%
Vanguard Fiduciary Trust Co 1.20M Mar 31, 2026 0.61% $0.00 0.00%
UBS Group AG 745.42K Mar 31, 2026 0.38% $0.00 1,429.79%
Amvescap Plc. 698.08K Mar 31, 2026 0.36% $0.00 1,209.89%
Nuveen, LLC 670.97K Mar 31, 2026 0.34% $0.00 -34.47%
Bank of America Corp 641.68K Mar 31, 2026 0.33% $0.00 535.74%
The Goldman Sachs Group Inc 555.91K Mar 31, 2026 0.28% $0.00 35.04%
Charles Schwab Investment Management Inc 480.60K Mar 31, 2026 0.24% $0.00 17.68%
Bank of New York Mellon Corp 478.37K Mar 31, 2026 0.24% $0.00 86.56%
Two Sigma Investments LLC 403.17K Mar 31, 2026 0.21% $0.00 -62.75%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 State Street® SPDR® S&P® Biotech ETF 8.62M 4.39% ▼ 2.17% Jun 30, 2026
2 Vanguard Total Stock Mkt Idx Inv 5.91M 3.00% ▲ 8.52% Jun 30, 2026
3 iShares Russell 2000 ETF 4.96M 2.52% ▲ 0.60% Jun 30, 2026
4 Vanguard Institutional Extnd Mkt Idx Tr 2.13M 1.09% ▲ 10.97% Jun 30, 2026
5 iShares Russell 2000 Growth ETF 1.74M 0.88% ▼ 0.38% Jun 30, 2026
6 Fidelity Small Cap Index 1.70M 0.87% ▲ 0.86% Apr 30, 2026
7 Russell 2000 Index Non-Lendable Fund 1.23M 0.62% ▲ 13.90% Jun 30, 2026
8 Russell 2000 Equity Index Fund B 1.23M 0.62% ▲ 13.90% Jun 30, 2026
9 State St Russell Sm/Mid Cp® Indx SL Cl I 1.11M 0.56% ▲ 8.84% Jun 30, 2026
10 Vanguard Russell 2000 ETF 1.09M 0.55% ▲ 23.02% Jun 30, 2026

Financial Highlights

Market Cap: $2.13B
Book Value: $0.59
Earnings/Share: $-0.23
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -25.45%
ROE (TTM): -43.59%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -82.50%

Valuation Metrics

Enterprise Value: $2.12B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 196.63M
Shares Float: 185.28M
% Insiders: 94.70%
% Institutions: 2,777.10%
Short % Float: 28.23%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Gross Profit
subtotal
$0.00
SG&A
adjust
$-12.25M
R&D
adjust
$-16.02M
Operating Income
subtotal
$-28.27M
Other / Non-Operating Items
adjust
$1.41M
Net Income
subtotal
$-26.86M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about SLS.US!